ReviewPharmaceutics2026
The Next Wave of Immunotherapy: A Critical Review of Nanotechnology Strategies for Immune Checkpoint Blockade.
Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The occurrence of cancer is continuing to rise globally and it has been estimated that cancer-related deaths can reach up to 16.3 million by 2040. The immune system has significant contribution in the fight against tumors; nonetheless, the capacity of tumors to escape the strong response induced by the immune system makes cancer a hard-to-treat disease. In recent times, cancer immunotherapy (IMT), particularly immune checkpoint inhibitors (ICPIs), has emerged as an innovative therapeutic approach in the oncology field; however, ICPIs suffer from several drawbacks that limit their therapeutic effectiveness. Therefore, it is crucial to develop a drug delivery system that can increase the therapeutic efficacy of ICPIs and decrease the side effects associated with their use. In order to develop a safe and effective cancer IMT, modifications of nano-biomaterials and development of nanocarrier (NC)-based drug delivery systems can overcome several challenges by improving bioavailability, delivering ICPIs toward targeted areas, enhancing the antitumor immunity, and achieving tumor microenvironment remodeling. NCs also have the potential to exert synergistic effects along with ICPIs. NCs can play a dual role by acting as a targeted delivery system and by combining therapies. The combination of NCs and ICPIs also has the potential to synergize with chemotherapy, radiation, embolization, and tumor ablation to optimize therapeutic outcomes and reduce treatment-associated toxicity. Therefore, this review has focused on revealing the potential of nanotechnology in the field of ICP blockade. In this review, various aspects including NC-mediated targeted delivery of ICPIs and applications of NCs as part of the combination IMT involving ICPIs have been extensively discussed based on numerous potential study findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.